Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 18

Results For "score"

904 News Found

Lilly issues urgent warning over potentially dangerous Tirzepatide-B12 compounds
News | March 14, 2026

Lilly issues urgent warning over potentially dangerous Tirzepatide-B12 compounds

Lilly has long voiced concerns over mass-compounded knockoffs of its tirzepatide medicines, Mounjaro and Zepbound


Shilpa Biologicals and mAbTree Biologics secure ODD from USFDA
Drug Approval | March 13, 2026

Shilpa Biologicals and mAbTree Biologics secure ODD from USFDA

Marks significant milestone for breakthrough biologic to treat rare blood cancers


World Glaucoma Week: Experts sound alarm over millions of undiagnosed cases in India
Healthcare | March 12, 2026

World Glaucoma Week: Experts sound alarm over millions of undiagnosed cases in India

Nearly 12 million people are estimated to be living with glaucoma, making the country one of the worst affected globally


Mumbai doctors perform India’s first robotic surgery to fix rare uterine defect in 23 year old
Hospitals | March 10, 2026

Mumbai doctors perform India’s first robotic surgery to fix rare uterine defect in 23 year old

Doctors recommended a robotic Strassmann Metroplasty, a reconstructive surgery that joins the two halves of the uterus into a single cavity capable of supporting pregnancy


FDA nod to Bristol Myers Squibb’s Sotyktu as new oral therapy for psoriatic arthritis
Drug Approval | March 10, 2026

FDA nod to Bristol Myers Squibb’s Sotyktu as new oral therapy for psoriatic arthritis

The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials


Bristol Myers Squibb reports positive phase 3 results for oral multiple myeloma therapy
Clinical Trials | March 10, 2026

Bristol Myers Squibb reports positive phase 3 results for oral multiple myeloma therapy

The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen


argenx reports breakthrough Phase 3 results for VYVGART in ocular myasthenia gravis
Clinical Trials | March 06, 2026

argenx reports breakthrough Phase 3 results for VYVGART in ocular myasthenia gravis

The trial met its primary endpoint, showing statistically significant improvements in Myasthenia Impairment Index (MGII) Patient-Reported Outcome (PRO) ocular scores at Week 4